Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Biomed Signal Process Control ; 77: 103745, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1944368

ABSTRACT

Background and objectives: The computed tomography (CT) scan facilities are crucial for diagnosis of pulmonary diseases and are overburdened during the current pandemic of novel coronavirus disease 2019 (COVID-19). LHSPred (Lung Health Severity Prediction) is a web based tool that enables users to determine a score that evaluates CT scans, without radiologist intervention, and predict risk of pneumonia with features of blood examination and age of patient. It can help in early assessment of lung health severity of patients without CT-scan results and also enable monitoring of post-COVID lung health for recovered patients. Methods: This tool uses Support Vector Regression (SVR) and Multi-Layer Perceptron Regression (MLPR), trained on COVID-19 patient data reported in the literature. It allows to compute a score (CT severity score) that evaluates the involvement of lesions in lung lobes and to predict risk of pneumonia. A web application was implemented that uses the trained regression models. Results: The application has proven to be effective and user friendly in a clinical setting for pulmonary disease treatment. The SVR model achieved Pearson correlation coefficient (PCC) of 0.77 and mean absolute error (MAE) of 2.239 while determining the computed tomography (CT) severity score. The MLPR model achieved PCC of 0.77 and MAE of 2.309. Thus, it can be applied as a useful tool in predicting pneumonia in the post COVID-19 era. Conclusion: LHSPred can be used as a decision support system by the clinicians and as a tool for self-assessment by the patients with only six blood test input features.

2.
Front Genet ; 12: 637362, 2021.
Article in English | MEDLINE | ID: covidwho-1119542

ABSTRACT

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus induced disease-2019 (COVID-19), is a type of common cold virus responsible for a global pandemic which requires immediate measures for its containment. India has the world's largest population aged between 10 and 40 years. At the same time, India has a large number of individuals with diabetes, hypertension and kidney diseases, who are at a high risk of developing COVID-19. A vaccine against the SARS-CoV-2, may offer immediate protection from the causative agent of COVID-19, however, the protective memory may be short-lived. Even if vaccination is broadly successful in the world, India has a large and diverse population with over one-third being below the poverty line. Therefore, the success of a vaccine, even when one becomes available, is uncertain, making it necessary to focus on alternate approaches of tackling the disease. In this review, we discuss the differences in COVID-19 death/infection ratio between urban and rural India; and the probable role of the immune system, co-morbidities and associated nutritional status in dictating the death rate of COVID-19 patients in rural and urban India. Also, we focus on strategies for developing masks, vaccines, diagnostics and the role of drugs targeting host-virus protein-protein interactions in enhancing host immunity. We also discuss India's strengths including the resources of medicinal plants, good food habits and the role of information technology in combating COVID-19. We focus on the Government of India's measures and strategies for creating awareness in the containment of COVID-19 infection across the country.

3.
Int Immunopharmacol ; 91: 107276, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-1023607

ABSTRACT

SARS-CoV-2 has a high transmission rate and shows frequent mutations, thus making vaccine development an arduous task. However, researchers around the globe are working hard to find a solution e.g. synthetic vaccine. Here, we have performed genome-wide analysis of 566 Indian SARS-CoV-2 genomes to extract the potential conserved regions for identifying peptide based synthetic vaccines, viz. epitopes with high immunogenicity and antigenicity. In this regard, different multiple sequence alignment techniques are used to align the SARS-CoV-2 genomes separately. Subsequently, consensus conserved regions are identified after finding the conserved regions from each aligned result of alignment techniques. Further, the consensus conserved regions are refined considering that their lengths are greater than or equal to 60nt and their corresponding proteins are devoid of any stop codons. Subsequently, their specificity as query coverage are verified using Nucleotide BLAST. Finally, with these consensus conserved regions, T-cell and B-cell epitopes are identified based on their immunogenic and antigenic scores which are then used to rank the conserved regions. As a result, we have ranked 23 consensus conserved regions that are associated with different proteins. This ranking also resulted in 34 MHC-I and 37 MHC-II restricted T-cell epitopes with 16 and 19 unique HLA alleles and 29 B-cell epitopes. After ranking, the consensus conserved region from NSP3 gene is obtained that is highly immunogenic and antigenic. In order to judge the relevance of the identified epitopes, the physico-chemical properties and binding conformation of the MHC-I and MHC-II restricted T-cell epitopes are shown with respect to HLA alleles.


Subject(s)
COVID-19 Vaccines/immunology , COVID-19/immunology , Epitopes, B-Lymphocyte/immunology , Epitopes, T-Lymphocyte/immunology , Genome, Viral/immunology , Immunogenicity, Vaccine/immunology , SARS-CoV-2/immunology , Amino Acid Sequence , Genome-Wide Association Study/methods , Humans , Vaccines, Synthetic/immunology
SELECTION OF CITATIONS
SEARCH DETAIL